BiotechTube

Ceftolozane/tazobactam

ApprovedTerminated
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Burns

Conditions

Burns, Pharmacokinetics

Trial Timeline

Aug 21, 2017 → Jun 30, 2020

NCT ID
NCT03002506

About Ceftolozane/tazobactam

Ceftolozane/tazobactam is a approved stage product being developed by Merck for Burns. The current trial status is terminated. This product is registered under clinical trial identifier NCT03002506. Target conditions include Burns, Pharmacokinetics.

What happened to similar drugs?

2 of 5 similar drugs in Burns were approved

Approved (2) Terminated (2) Active (3)
✅Sulfamylon® For 5 % Topical Solution + Topical Antimicrobial/Antifungal MedicationsViatrisApproved
✅Pathogen-Reduced Plasma + Crystalloid SolutionsCerusApproved
🔄Ciprofloxacin (BAYO9867) + Ciprofloxacin (BAYO9867)BayerPhase 3
🔄NexoBrid + Gel VehicleMediWoundPhase 3
🔄NexoBridMediWoundPhase 3

Hype Score Breakdown

Clinical
20
Activity
0
Company
15
Novelty
0
Community
0

Clinical Trials (4)

NCT IDPhaseStatus
NCT04223752Phase 1Completed
NCT03002506ApprovedTerminated
NCT02620774Phase 1Completed
NCT02421120ApprovedCompleted

Competing Products

12 competing products in Burns

See all competitors
ProductCompanyStageHype Score
R-Pdf/Gbb 0.01% gelJohnson & JohnsonPhase 2
31
linezolidPfizerPhase 1
29
Somatropin + 0.09% Saline SolutionPfizerPhase 2/3
38
Ciprofloxacin (BAYO9867) + Ciprofloxacin (BAYO9867)BayerPhase 3
37
cP12United TherapeuticsPhase 2
39
cNP8United TherapeuticsPhase 1
26
Sulfamylon® For 5 % Topical Solution + Topical Antimicrobial/Antifungal MedicationsViatrisApproved
32
Sheet skin grafts affixed with Fibrin Sealant (lyophilized) with 4 IU/mL ThrombinBaxterPhase 1/2
29
I-020502BaxterPhase 2
32
Pathogen-Reduced Plasma + Crystalloid SolutionsCerusApproved
25
NexoBrid + Gel VehicleMediWoundPhase 3
30
NexoBridMediWoundPhase 3
30